• Rapid Test

    • For bacteria presence, concentration, presumptive ID and antimicrobial susceptibility against 6 candidate antimicrobials
    • Rapid test result available within 1 hour of testing, and emailed/faxed back to you on the same day as sample pickup
  • Culture Test

    • Culture test for bacteria presence (including polymicrobial samples), concentration, ID and antimicrobial susceptibility against 6 candidate antimicrobials
    • Culture test result available within 48 hours of testing
  • Costs

    • $60/test for both the rapid test and the culture test; similar to the costs charged by other reference laboratories for the culture test alone
    • Please send us an inquiry for volume discounts, and for other questions
  • Service Region

    • Currently, we are offering our service in the Southern California region only.
    • In the future, we will expand our offering to include a test kit that can be housed in your facility, and used by your personnel.  Please send us an email if you would like this offering.

Clinical Use

  • Urinary tract infections ~ causative organism

    • Animals (both companion and farm use animals) suffer from urinary tract infections.
    • Retrospective studies have documented the most common species of uropathogens in dogs and cats, with Escherichia coli being the single most common pathogen in both acute and recurrent UTIs.
    • The other common pathogens include StaphylococcusProteusStreptococcusKlebsiella, and Pseudomonas spp.
    • In UTIs in horses, E coliStreptococcus, and Enterococcus spp predominate, whereas Corynebacterium renale and E coli are the most common pathogens in ruminants.
    • In immunocompromised animals, funguria from Candida spp may occur.
    • E. coli is thus the most prevalent organism in animal urine samples (and separately, also in human urine sample)

    Reference:  https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-urinary-system/bacterial-urinary-tract-infections

    Antimicrobial therapy

    • Antimicrobials are the cornerstone of UTI therapy
    • Indications to treat with antimicrobials include visualization of bacteria in the urine, evidence of pyuria, dilute urine (<1.013 SG), or select other conditions that can be rapidly diagnosed with a “urinalysis test”.
    • However, the urinalysis does not indicate pathogen concentration, or provide any antimicrobial susceptibility information
    • Thus, in addition to initiating treatment with an initial course of antibiotics, culture and susceptibility testing should also be initiated .
    • Treatment failures are relatively common, and are either due to poor owner compliance, or to antimicrobial resistance.  Thus, culture testing to characterize antimicrobial susceptibility is routinely done.
  • Benefits of rapid antimicrobial susceptibility testing

    • Studies of human patients with acute pyelonephritis (an infection in the upper urinary tract) revealed the following:  (1)  Such patients are generally infected with E. coli.   As per one study, 96% of patients with APN without additional complications were infected with E. coli. (2) However, these patients often present with a resistant strain of E. coli (6.3% and 19.9% of patients with uncomplicated and complicated pyelonephritis had fluoroquinolone resistance, and 2.6% and 12.2% had an extended-spectrum β-lactamase (ESBL)-producing strain, respectively).  (3) Currently, susceptibility testing takes 24-72 hours, meaning that some patients infected with resistant uropathogens could be initially treated with ineffective antibiotics for the critical first days of their illness. In the same study, a substantial proportion of outpatients (45% of those with fluoroquinolone resistance and 75% of those with ESBL production) were initially treated with in vitro inactive drugs. (4) Of note, in a previous clinical trial of outpatients with APN, initial empirical treatment (i.e., while awaiting culture and susceptibility results) with an in vitro inactive antibiotic was associated with a clinical cure rate of 35% compared to 92% among those treated initially with an in vitro active antibiotic.
    • Thus, there is significant benefit (in terms of clinical outcomes) to having the antimicrobial susceptibility information as quickly as possible.  We are not aware of any data with respect to animal urine samples, but the clinical benefit should be similar to that seen in humans (clinical cure rates of 92% vs 35%).


    Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ. 2016. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase–Producing Escherichia coli Infections in Patients with Pyelonephritis, United States1. Emerg Infect Dis 22:1594–1603.

    Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. 2000. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 283:1583–1590.

Laboratory standards

Our unique combination of in-house technology and experience enables value to you

  • Standards – We are equipped with reference standards from several standards organizations, including Standard Waters and Methods, ASTM, FDA BAM, US Pharmacopeia, WHO Standards, British Pharmacopeia, CLSI

  • Licensed personnel – We are qualified microbiologists and engineers.  Our clinical microbiology procedures are supervised by a licensed CLS (see attached picture), with several years experience managing a large clinical microbiology laboratory attached to an acute care hospital in the Southern California region.  Our engineering procedures are supervised by a PhD engineer.

  • Time to result – Our proprietary reagent and hardware tools enables a rapid test turn around time.  No other reference laboratory can provide you with this rapid test result.